Methylene Blue Extravasation During Parathyroidectomy Reveals Critical Safety Gap
A case report from Surrey and Sussex NHS Trust highlights risks of methylene blue extravasation into hand and forearm during parathyroid surgery.
Summary
This case report from Surrey and Sussex NHS Trust describes an incident in which methylene blue — used intraoperatively to identify parathyroid tissue — extravasated into the hand and forearm of a patient undergoing parathyroidectomy. The authors detail the clinical management undertaken, compare their approach to similar published cases, and stress the absence of standardised national guidance for managing such complications. Methylene blue is an off-label dye used in parathyroid surgery to aid gland identification, but its extravasation can cause local tissue injury. The case underscores the importance of vigilant intravenous access monitoring during administration, and the authors call for the development of formal protocols to guide clinicians when this adverse event occurs.
Detailed Summary
Methylene blue is occasionally used as an intraoperative adjunct during parathyroidectomy to help surgeons visually identify parathyroid tissue, exploiting its selective uptake by these glands. While generally considered useful, its administration carries risks — particularly when delivered intravenously through a peripheral cannula that may not be fully patent.
This case report from the Department of Anaesthesia and the Department of Ear Nose and Throat Surgery at Surrey and Sussex NHS Trust describes a patient who experienced methylene blue extravasation into the hand and forearm during elective parathyroidectomy. The extravasation was identified perioperatively, prompting immediate clinical intervention. The authors outline the management steps taken, which included local wound care and monitoring for signs of tissue damage such as necrosis or compartment syndrome.
Comparing their case to previously published reports, the authors note that methylene blue extravasation is a recognised but uncommon complication, with outcomes ranging from minor staining and irritation to significant tissue injury requiring surgical debridement. The cytotoxic and oxidative properties of methylene blue at high local concentrations can damage soft tissue, making prompt recognition and management essential.
A central concern raised by the authors is the lack of standardised national guidance in the UK for managing methylene blue extravasation specifically in the surgical context. While general extravasation protocols exist for chemotherapy agents, no equivalent framework addresses this dye in parathyroid surgery. This gap means clinical teams may respond inconsistently, potentially delaying appropriate care.
The authors advocate for the development of clear, evidence-based protocols that outline steps for immediate management — including elevation, aspiration, hyaluronidase use if appropriate, and specialist referral thresholds — to ensure patient safety and optimise outcomes when this complication arises.
Key Findings
- Methylene blue extravasated into a patient's hand and forearm during routine parathyroidectomy at a UK NHS Trust.
- The case was managed clinically, with monitoring for tissue necrosis and compartment syndrome.
- Comparison with published literature confirms methylene blue extravasation is rare but potentially injurious.
- No standardised national UK guidance currently exists for managing methylene blue extravasation in surgery.
- Authors call for formal protocols to ensure consistent, safe clinical response to this complication.
Methodology
This is a single-centre case report describing one patient's perioperative experience at Surrey and Sussex NHS Trust. The authors supplement the case narrative with a review of comparable published cases to contextualise management decisions. No comparative cohort or control group is included.
Study Limitations
As a single case report, findings cannot be generalised and represent only one clinical scenario and management approach. The full text was unavailable in XML form, limiting detailed extraction of clinical data, dosing, and outcome metrics. Evidence base for optimal management of methylene blue extravasation remains limited to small case series and anecdotal reports.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.